Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.955 SEK | +2.25% | -26.12% | -61.42% |
04-15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
04-04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Sales 2023 | 35.2M 3.22M 258M | Sales 2024 * | 105M 9.6M 769M | Capitalization | 292M 26.68M 2.13B |
---|---|---|---|---|---|
Net income 2023 | -249M -22.76M -1.82B | Net income 2024 * | -244M -22.3M -1.78B | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.12M 490M | Net cash position 2024 * | 208M 18.98M 1.52B | EV / Sales 2024 * | 0.8 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-1.94
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.37% |
Latest transcript on Oncopeptides AB
1 day | +2.25% | ||
1 week | -26.12% | ||
Current month | -54.54% | ||
1 month | -44.01% | ||
3 months | -56.45% | ||
6 months | -57.79% | ||
Current year | -61.42% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 31/07/20 |
Director of Finance/CFO | 50 | 11-12 | |
Eva Nordström
COO | Chief Operating Officer | 54 | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 16/05/18 |
Director/Board Member | 63 | 31/12/11 | |
Director/Board Member | 61 | 31/01/17 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 2.955 | +2.25% | 1,303,488 |
25/04/24 | 2.89 | -10.25% | 2,636,199 |
24/04/24 | 3.22 | +2.06% | 2,526,246 |
23/04/24 | 3.155 | -11.62% | 1,053,101 |
22/04/24 | 3.57 | -10.75% | 763,366 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.42% | 26.62M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ONCO Stock